Sign in
Taking peopleNo phase

Prehospital Resuscitation Intranasal Cooling Effectiveness Survival Study 2

Key facts

Who runs it
Karolinska Institutet
Where
Austria, Belgium, Germany, Italy, Norway, Slovenia, Spain, and Sweden17 sites in 8 countriesChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
1,022 people, planned
Started
27 Mar 2024
Expected to end
May 2028
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Early transnasal evaporative cooling with the RhinoChill device
Record updated
16 September 2026

Who can take part

Age
18 years to 79 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Patients ≥18 years that meet all of the following inclusion criteria:
  • Adult out-of-hospital cardiac arrest patients with initial shockable rhythm
  • Unconsciousness defined as Glasgow Coma Scale < 8
  • Inclusion within 20 minutes from EMS arrival

Who cannot take part

  • Obvious non-cardiac causes to cardiac arrest
  • Have a known terminal disease
  • Age ≥ 80 years
  • Patients are not eligible if they meet one or more of the following criteria:
  • Obvious already hypothermic
  • Obvious barrier to placing intra nasal catheters
  • Have a known Do Not Attempt to Resuscitate (DNAR) order or other limitations in care
  • Known or clinically apparent pregnancy

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 79 years old?

This trial has no sites in United States.

It has sites in 8 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of this clinical trial is to study the impact of ultra-early transnasal evaporative cooling after cardiac arrest and subsequent hypothermia at hospital, on survival with complete neurologic recovery, compared to currently recommended normothermia. The study population will consist of patients 18-79 years old, with out-of-hospital cardiac arrest with initial shockable rhythm.

Read full original descriptionShow less

The main research question it aims to answer is whether there is a difference in survival with complete neurologic recovery at 90 days after cardiac arrest between the group of patients that received ultra-early cooling, compared to the group that was treated with normothermia.

Participants will be randomized to two groups. One group (the intervention group) will receive ultra-early trans-nasal evaporative cooling initiated by EMS personnel at the scene of the cardiac arrest, and subsequent systemic hypothermia for 24 hours at hospital arrival. The other group (the control group), will receive standard of care (advanced cardiac life support and normal body temperature (normothermia)).

The 2 groups in the trial

  • Early transnasal evaporative cooling with the RhinoChill deviceTreatment being tested

    Early transnasal evaporative cooling initiated during ACLS at the scene of the cardiac arrest within 20 minutes from EMS arrival and subsequent hypothermia at 33ºC for 24 hours and fever control for 72 hours at the ICU

  • Standard of careNo study treatment, for comparison

    Standard advanced cardiac life support, subsequent fever control (Normothermia) for 72 hours at ICU

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Prehospital Resuscitation Intranasal Cooling Effectiveness Survival Study 2 (PRINCESS2)
Criteria questions
Built from NCT06025123, who can take part
Publications
Record updated
16 September 2026